The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Open accessPublished version of a preprint
Abstract
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in 18% (13/71) of patients. Overall, 30% (21/71) of enrolled patients experienced a change in clinical management as a result of genomic data. Twenty-six patients had germline and/or somatic alterations in DNA-damage repair genes, and 5 additional patients had mutational signatures of homologous recombination deficiency but no identified causal genomic alteration. Two patients had oncogenic in-frame BRAF deletions, and we report the first clinical evidence that this alteration confers sensitivity to MAPK pathway inhibition. Moreover, we identified tumor/stroma gene expression signatures with clinical relevance. Collectively, these data demonstrate the feasibility and value of real-time genomic characterization of advanced PDAC. Significance: Molecular analyses of metastatic PDAC tumors are challenging due to the heterogeneous cellular composition of biopsy specimens and rapid progression of the disease. Using an integrated multidisciplinary biopsy program, we demonstrate that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease. Cancer Discov; 8(9); 1096–111. ©2018 AACR. See related commentary by Collisson, p. 1062. This article is highlighted in the In This Issue feature, p. 1047
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are also so-called “alternative drivers” found in the 8–10% of cases that are KRAS wild type104,105.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Self-citationCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×
“As has been suggested in prior studies of primary PDAC resection specimens (7,9,12), we observed a striking prevalence of germline and somatic mutations in DDR genes in our cohort of advanced PDAC patients.”
BackgroundResultMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,520
Self-citationOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Cited by
Sorted by citations
Park, W., Chawla, A., & O'Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 2,040
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Molecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., González-Pérez, A., López-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 858
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Lowder, K. E., Galvez-Reyes, J., Kalekar, R. L., Mulugeta, N., Kapner, K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.017 · Cited by 592
Self-citationPishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E. E., DeArbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sahai, V., Sohal, D. P. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30074-7 · Cited by 564
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C. H., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 500
Targeting Alterations in the RAF–MEK Pathway
Yaeger, R. D., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 491
Self-citationTherapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348
Advancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 357
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes
Heo, Y. J., Hwa, C., Lee, G.-H., Park, J.-M., & An, J.-Y. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0042 · Cited by 294
SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update)
Oscanoa, J., Sivapalan, L., Gadaleta, E., Ullah, A. Z. M. D., Lemoine, N. R., & Chelala, C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa420 · Cited by 275
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Self-citationThe Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alhamwe, B. A., von Strandmann, E. P., Slater, E. P., Bartsch, J. W., Bauer, C. A., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 250
Rashid, N. U., Peng, X. L., Jin, C., Moffitt, R. A., Volmar, K. E., Belt, B. A., Panni, R. Z., Nywening, T. M., Herrera, S. G., Moore, K. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1467 · Cited by 239
Self-citationPark, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 247
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Grant, R. C., Merico, D., Lungu, I. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 227
Self-citationKarasinska, J. M., Topham, J. T., Kalloger, S. E., Jang, G. H., Denroche, R. E., Culibrk, L., Williamson, L. M., Wong, H., Lee, M. K. C., O'Kane, G. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1543 · Cited by 215
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer
Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., Lucas, F. A. S., Fernandes, C. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126915 · Cited by 176
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Self-citationNew Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 157
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
Störz, P., & Crawford, H. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.059 · Cited by 154
Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., Golan, T., Braconi, C., Froeling, F. E. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03238 · Cited by 149
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 139
Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128
PDX-derived organoids model in vivo drug response and secrete biomarkers
Huang, L., Bockorny, B., Paul, I., Akshinthala, D., Frappart, P., Gandarilla, O., Bose, A., Sanchez‐Gonzalez, V., Rouse, E. E., Lehoux, S. D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135544 · Cited by 138
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L. B., Huang, L., Akshinthala, D., Perea, S., González, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 128
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Miyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 124
Self-citationBlasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
Lomberk, G. A., Dusetti, N., Iovanna, J., & Urrutia, R. A. (2019) · Nature Communications · doi:10.1038/s41467-019-11812-7 · Cited by 101
Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 105
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01732-6 · Cited by 105
Williams, H. L., Costa, A. D., Zhang, J., Raghavan, S., Winter, P. S., Kapner, K. S., Ginebaugh, S. P., Väyrynen, S. A., Väyrynen, J. P., Yuan, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-3050 · Cited by 100
Self-citationAl Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94
Leiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 99
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Self-citationCancer biology as revealed by the research autopsy
Iacobuzio–Donahue, C. A., Michael, C., Baez, P., Kappagantula, R. L., Hooper, J. E., & Hollman, T. J. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0199-4 · Cited by 89
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 97
Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
Klaiber, U., Leonhardt, C.-S., Strobel, O., Tjaden, C., Hackert, T., & Neoptolemos, J. P. (2018) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-018-1724-8 · Cited by 85
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
Ely, Z. A., Kulstad, Z. J., Günaydın, G., Addepalli, S., Verzani, E. K., Casarrubios, M., Clauser, K. R., Wang, X., Lippincott, I. E., Louvet, C., et al. (2025) · Science · doi:10.1126/science.adk3487 · Cited by 88
Self-citationGout, J., Perkhofer, L., Morawe, M., Arnold, F., Ihle, M., Biber, S., Lange, S., Roger, É., Kraus, J. M., Stifter, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319970 · Cited by 83
Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 80
Martens, S., Lefesvre, P., Nicolle, R., Biankin, A. V., Puleo, F., Laethem, J. V., & Rooman, I. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz181 · Cited by 78
The Future of Precision Oncology
Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612613 · Cited by 92
Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 90
McIntyre, C. A., Lawrence, S., Richards, A. L., Chou, J. F., Wong, W., Capanu, M., Berger, M. F., Donoghue, M. T. A., Yu, K. H., Varghese, A. M., et al. (2020) · Cancer · doi:10.1002/cncr.33038 · Cited by 75
Qiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.038 · Cited by 75
Self-citationATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 78
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 70
Law, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 71
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2020) · Pancreatology · doi:10.1016/j.pan.2020.12.017 · Cited by 73
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 68
Bhola, P. D., Ahmed, E., Guerriero, J. L., Sicińska, E., Su, E., Lavrova, E., Ni, J., Chipashvili, O., Hagan, T., Pioso, M. S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aay1451 · Cited by 66
Self-citationCharacterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103897 · Cited by 62
Rong, Y., Gao, J., Kuang, T., Chen, J., Li, J.-A., Huang, Y., Xin, H., Fang, Y., Han, X., Sun, L., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16196 · Cited by 61
Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
Federico, A. D., Tateo, V., Parisi, C., Formica, F., Carloni, R., Frega, G., Rizzo, A., Ricci, D., Marco, M. D., Palloni, A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14070677 · Cited by 61
Jain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 64
Rainone, M., Singh, I., Salo‐Mullen, E. E., Stadler, Z. K., & O'Reilly, E. M. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5963 · Cited by 60
PARP Inhibitors in Pancreatic Cancer
Brown, T. J., & Reiss, K. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000554 · Cited by 55
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology
Dantes, Z., Yen, H.-Y., Pfarr, N., Winter, C., Steiger, K., Muckenhuber, A., Hennig, A., Lange, S., Engleitner, T., Öllinger, R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137809 · Cited by 53
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 52
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 57
Pishvaian, M. J., Wang, H., He, A. R., Hwang, J. J., Smaglo, B. G., Kim, S. S., Weinberg, B. A., Weiner, L. M., Marshall, J. L., & Brody, J. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1301 · Cited by 48
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
Silvis, M. R., Silva, D., Rohweder, R., Schuman, S. S., Gudipaty, S. A., Truong, A., Yap, J. T., Affolter, K. E., McMahon, M., & Kinsey, C. G. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221524 · Cited by 46
Jain, A. S., Prasad, A., Pradeep, S., Dharmashekar, C., Achar, R. R., Silina, E. V., Stupin, V. A., Amachawadi, R. G. G., Prasad, S. K., Pruthvish, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741326 · Cited by 51
Shinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Singh, H., Keller, R. B., Kapner, K. S., Dilly, J., Raghavan, S., Yuan, C., Cohen, E. F., Tolstorukov, M. Y., Andrews, E., Brais, L. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3930 · Cited by 53
Self-citationPoly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer
Jain, A., Agostini, L. C., McCarthy, G. A., Chand, S. N., Ramirez, A., Nevler, A., Cozzitorto, J. A., Schultz, C. W., Lowder, C. Y., Smith, K. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3645 · Cited by 46
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Yoshimura, A., Imoto, I., & Iwata, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137481 · Cited by 48
Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R. B., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3034 · Cited by 45
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 48
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Ono, H., Kato, T., Murase, Y., Nakamura, Y., Ishikawa, Y., Watanabe, S., Akahoshi, K., Ogura, T., Ogawa, K., Ban, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89530-8 · Cited by 45
Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F. R., Cooke, S., Marshall, J., Beraldi, D., Knight, S. R., Upstill‐Goddard, R., Dickson, E. J., et al. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.04.06 · Cited by 43
Adamopoulos, C., Cave, D. D., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031631 · Cited by 43
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 47
Self-citationSakakida, T., Ishikawa, T., Doi, T., Morita, R., Kataoka, S., Miyake, H., Yamaguchi, K., Moriguchi, M., Sogame, Y., Yasuda, H., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01986-9 · Cited by 43
Cancer tissue of origin constrains the growth and metabolism of metastases
Sivanand, S., Gültekin, Y., Winter, P. S., Vermeulen, S. Y., Tchourine, K., Abbott, K. L., Danai, L. V., Gourgue, F., Do, B. T., Crowder, K. D., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01105-9 · Cited by 46
Self-citationChittenden, A. B., Haraldsdóttir, S., Ukaegbu, C. I., Underhill-Blazey, M. L., Gaonkar, S., Uno, H., Brais, L. K., Perez, K. J., Wolpin, B. M., Syngal, S., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00678 · Cited by 42
Self-citationTherapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future
Barhli, A., Cros, J. F., Bartholin, L., & Neuzillet, C. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.009 · Cited by 40
Evolving pancreatic cancer treatment: From diagnosis to healthcare management
Milella, M., Bassi, C., Boggi, U., Brunetti, O., Cavaliere, A., Crippa, S., Vita, F. D., Falconi, M., Frassineti, G. L., Giommoni, E., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103571 · Cited by 37
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 39
Self-citationGenomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer
Sarkar, N. D., Dasgupta, S., Chatterjee, P., Coleman, I. M., Ha, G., Ang, L. S., Kohlbrenner, E. A., Frank, S. B., Nunez, T. A., Salipante, S. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152789 · Cited by 37
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Moving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
Masuda, S., Koizumi, K., Shionoya, K., Jinushi, R., Makazu, M., Nishino, T., Kimura, K. A., Sumida, C., Kubota, J., Ichita, C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1863 · Cited by 33
Fusco, M. J., Saeed‐Vafa, D., Carballido, E. M., Boyle, T. A., Malafa, M. P., Blue, K., Teer, J. K., Walko, C. M., McLeod, H. L., Hicks, J. K., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00265 · Cited by 34
Metadata
- Authors
- Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., Welch, M. W., Reilly, E., McCabe, D., Marini, L., Anderka, K., Helvie, K., Oliver, N., Babic, A., Da Silva, A., Nadres, B., Van Seventer, E. E., Shahzade, H. A., St. Pierre, J. P., Burke, K. P., Clancy, T., Cleary, J. M., Doyle, L. A., Jajoo, K., McCleary, N. J., Meyerhardt, J. A., Murphy, J. E., Ng, K., Patel, A. K., Perez, K., Rosenthal, M. H., Rubinson, D. A., Ryou, M., Shapiro, G. I., Sicinska, E., Silverman, S. G., Nagy, R. J., Lanman, R. B., Knoerzer, D., Welsch, D. J., Yurgelun, M. B., Fuchs, C. S., Garraway, L. A., Getz, G., Hornick, J. L., Johnson, B. E., Kulke, M. H., Mayer, R. J., Miller, J. W., Shyn, P. B., Tuveson, D. A., Wagle, N., Yeh, J. J., Hahn, W. C., Corcoran, R. B., Carter, S. L., & Wolpin, B. M.
- Affiliations
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Stony Brook University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- 1Dana-Farber Cancer Institute, Boston, Massachusetts.
- 9Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
- Guardant (United States) (US)
- 14BioMed Valley Discoveries, Kansas City, Missouri.
- Harvard University (US)
- Cold Spring Harbor Laboratory (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Aguirre, Andrew J.
- Carter, Scott L.
- Wolpin, Brian M.
- ORCID
- Aguirre, Andrew J.
- Nowak, Jonathan A.
- Camarda, Nicholas D.
- Moffitt, Richard A.
- Ghazani, Arezou A.
- Hazar-Rethinam, Mehlika
- Raghavan, Srivatsan
- Kim, Jaegil
- Brais, Lauren K.
- Reilly, Emma
- McCabe, Devin
- Helvie, Karla
- Nadres, Brandon
- Burke, Kelly P.
- Clancy, Thomas
- Cleary, James M.
- Doyle, Leona A.
- McCleary, Nadine J.
- Meyerhardt, Jeffrey A.
- Ng, Kimmie
- Patel, Anuj K.
- Perez, Kimberly
- Rosenthal, Michael H.
- Rubinson, Douglas A.
- Ryou, Marvin
- Shapiro, Geoffrey I.
- Silverman, Stuart G.
- Nagy, Rebecca J.
- Lanman, Richard B.
- Knoerzer, Deborah
- Yurgelun, Matthew B.
- Fuchs, Charles S.
- Garraway, Levi A.
- Getz, Gad
- Hornick, Jason L.
- Johnson, Bruce E.
- Kulke, Matthew H.
- Mayer, Robert J.
- Miller, Jeffrey W.
- Shyn, Paul B.
- Tuveson, David A.
- Wagle, Nikhil
- Yeh, Jen Jen
- Hahn, William C.
- Corcoran, Ryan B.
- Carter, Scott L.
- Wolpin, Brian M.
- Venue
- Cancer Discovery
- Published
- 2018-09-01
- Volume
- 8
- Issue
- 9
- Pages
- 1096-1111
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6192263
- OpenAlex
- W2808191072
- Cited by
- 367
- References
- 55
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 38 · 2023: 48 · 2022: 58 · 2021: 70 · 2020: 52 · 2019: 34 · 2018: 10
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- Lustgarten Foundation
- Noble Effort Fund
- Peter R. Leavitt Family Fund
- Wexler Family Fund
- Promises for Purple
- HHS | NIH | National Cancer Institute (NCI) (P50CA127003, U01CA224146, U01CA210171, R01CA199064, K08CA2118420-01)
- Pancreatic Cancer Action Network (PanCAN)
- Hale Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute
- Hope Funds for Cancer Research
- Doris Duke Charitable Foundation (DDCF)
- Conquer Cancer Foundation (CCF)
- Broman Fund for Pancreatic Cancer Research
- Harvard Clinical and Translational Sciences Center (UL1 TR001102)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, advanced pancreatic cancer, precision medicine, exome sequencing, RNA sequencing, germline alterations, somatic alterations, DNA repair genes, homologous recombination deficiency, mutational signatures, MAPK inhibition, biopsy protocol, metastatic cancer
- MeSH terms
- Exome Sequencing, Adult, Aged, Aged, 80 and over, DNA Repair, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Genetic Variation, Gene Expression Regulation, Neoplastic, Sequence Analysis, RNA, Germ-Line Mutation, Gene Expression Profiling, MAP Kinase Signaling System, Carcinoma, Pancreatic Ductal, Genomics, Gene Regulatory Networks, Precision Medicine, Homologous Recombination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
